Form 4: Precision Biosciences Director Shari Lisa Pire Reports RSU Vesting and New Equity Grant

Precision Biosciences, Inc. Director Shari Lisa Pire reported the vesting of 9,826 Restricted Stock Units into common stock and the grant of an additional 21,000 Restricted Stock Units.

Summary

• Shari Lisa Pire, a Director at Precision Biosciences, Inc. (DTIL), reported changes in her beneficial ownership through a Form 4 filing.
• On May 27, 2025, 9,826 Restricted Stock Units (RSUs) vested, converting into 9,826 shares of the company's common stock.
• These vested RSUs were originally granted on June 4, 2024, and their vesting was contingent on Ms. Pire's continued service to the Issuer.
• Following this transaction, Ms. Pire directly holds 14,028 shares of common stock.
• Additionally, on June 3, 2025, Ms. Pire was granted 21,000 new Restricted Stock Units.
• These newly granted RSUs are scheduled to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, also subject to her continued service.
• After the new grant, Ms. Pire beneficially owns 21,000 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects ongoing director engagement and standard equity compensation practices, which are generally viewed favorably for aligning insider interests with shareholders. There are no negative implications from this routine disclosure.

Positives

• The vesting of RSUs indicates the fulfillment of service conditions by a director, reflecting continued commitment to the company.
• The grant of new RSUs aligns the director's long-term interests with those of shareholders by providing equity-based incentives.

Future Outlook

The filing indicates future vesting events for the newly granted Restricted Stock Units, contingent on the director's continued service to the company, aligning future compensation with long-term performance.

Industry Context

This filing is a standard disclosure of insider equity compensation within the biotechnology industry, where equity-based incentives like Restricted Stock Units are common for attracting and retaining key talent, including directors, to align their interests with long-term company growth and innovation.

Related Party Transactions

• The grant and vesting of Restricted Stock Units to a director constitutes a related party transaction, as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The RSU vesting and grant align the director's interests with shareholders by tying compensation to company performance and long-term value creation. It also indicates a director's continued commitment to the company.
• Employees: While not directly impacting all employees, the use of equity compensation for directors sets a precedent for similar incentive structures within the company.

Next Steps

• The 21,000 new Restricted Stock Units are expected to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

Keywords

Precision Biosciences, DTIL, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Grant, Director Compensation, Beneficial Ownership, Biotechnology